Medication info
Empa Duo Tablet 5/500 mg (Empagliflozin, Metformin Hydrochloride)

Empa Duo Tablet 5/500 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Donggu Bio Pharmaceutical Co., Ltd.
Appearance
Orange-yellow, oval, bi-convex film-coated tablets
Packaging
10 tablets/box [10 tablets/PTP x 1], 60 tablets/box [10 tablets/PTP x 6], 30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202201297 · Approved 2022.04.04 · Insurance code 657309070

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from concomitant treatment with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin as they were previously taking. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated using the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be closely monitored every 3-6 months (see Precautions for Use 3. Patients Requiring Caution, subsection 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients Who Must Not Take This Medicine, subsection 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Donggu Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood glucose control
  • cardiovascular disease
  • cardiovascular events
View approved original text

This medication is used in conjunction with diet and exercise to effectively control blood sugar for patients with type 2 diabetes. It combines Empagliflozin and Metformin, particularly for adult type 2 diabetes patients whose blood sugar is not adequately controlled and who may have cardiovascular disease, as indicated in the professional information regarding cardiovascular event caution. Therefore, this drug helps improve blood sugar control, along with cardiovascular risk management in adult patients with type 2 diabetes.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from concomitant treatment with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin as they were previously taking. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated using the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be closely monitored every 3-6 months (see Precautions for Use 3. Patients Requiring Caution, subsection 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients Who Must Not Take This Medicine, subsection 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication is helpful for controlling blood sugar; however, certain important precautions must be followed when taking it. First, this medication can cause a dangerous condition known as lactic acidosis. Lactic acidosis occurs when there is an excessive buildup of lactic acid in the body, which can be very serious and may sometimes lead to death. Thus, it is safe not to use this drug in patients with impaired kidney function or problems with the heart, liver, or lungs. Additionally, there is a risk of hypoglycemia when using this drug together with insulin or other blood glucose-lowering agents. Hypoglycemia can cause dizziness, cold sweats, and in severe cases, loss of consciousness. This drug should only be administered to patients with normal kidney function, and patients with moderate to severe impaired kidney function should not take it. Since kidney function can vary, it is important to monitor kidney status through regular blood tests. If surgery is planned or if a test involves iodine contrast agents, this medication should be discontinued for a certain period before and after the test. This is because it can put stress on the kidneys and increase the risk of lactic acidosis. Pregnant or breastfeeding women are advised not to use this drug. During pregnancy, insulin therapy is recommended for blood glucose control. During the use of this medication, if conditions such as dehydration, severe infection, or heart failure occur, you should immediately consult a doctor and discontinue the drug. Additionally, alcohol consumption should be avoided as it can increase the risk of lactic acidosis. This medication may increase the risk of urinary tract infections and genital infections, so treatment should be sought promptly if infection symptoms arise. Moreover, this medication can decrease vitamin B12 levels, so it is advisable to have regular testing for vitamin B12 levels if taken long-term. Elderly patients or those with weak kidney function should adjust the dosage of this drug, and regular kidney function tests are necessary. In cases of overdose, serious side effects such as lactic acidosis may occur, so the dosage must be carefully adhered to, and hospital visits should be made immediately if unusual symptoms occur. Finally, this medication should be stored out of reach of children, and kept in its original container to maintain quality.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 164 more
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema and angioedema
  • difficulty urinating
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • ketosis
  • lactic acidosis
  • decreased fluid volume
  • perineal gangrene
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • lower gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • adnexal-ovarian abscess
  • vestibular neuronitis
  • headache
  • sensory deficit
  • orthostatic dizziness
  • dizziness
  • drowsiness
  • weakness
  • chest discomfort
  • chest pain
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight loss
  • urinary stones
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypoglycemic episodes
  • decreased appetite
  • obesity
  • acanthosis nigricans
  • diabetes mellitus
  • hyperlipidemia
  • hyponatremia
  • vitamin D deficiency
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • conjunctival congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • residual sputum
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina pectoris
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodules
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to keep it at room temperature between 1 to 30 degrees Celsius. This way, the drug's effectiveness and safety can be maintained for a long time.

Appearance and packaging

Appearance

Orange-yellow, oval, bi-convex film-coated tablets

Package unit

10 tablets/box [10 tablets/PTP x 1], 60 tablets/box [10 tablets/PTP x 6], 30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.